[{"id":"627558e9-c3d7-4f51-90e5-5a44fbbddb52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351103","created_at":"2021-01-18T05:31:16.537Z","updated_at":"2024-07-02T16:34:59.934Z","phase":"Phase 1","brief_title":"A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands","source_id_and_acronym":"NCT01351103","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF • RNF43","pipe":" | ","alterations":" BRAF mutation • RNF43 mutation","tags":["BRAF • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • WNT974"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 06/18/2024","study_completion_date":" 06/18/2024","last_update_posted":"2024-05-30"},{"id":"db9772f8-853e-4276-a288-f8213fb1a0f0","acronym":"PORCUPINE","url":"https://clinicaltrials.gov/study/NCT04907539","created_at":"2021-05-28T13:52:49.332Z","updated_at":"2024-07-02T16:35:06.261Z","phase":"Phase 2","brief_title":"A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)","source_id_and_acronym":"NCT04907539 - PORCUPINE","lead_sponsor":"Redx Pharma Plc","biomarkers":" RNF43 • RSPO2","pipe":"","alterations":" ","tags":["RNF43 • RSPO2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Prolia (denosumab) • zamaporvint (RXC004)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 04/02/2024","primary_completion_date":" 04/02/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2024-05-03"},{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"f206d692-a2fb-4635-9598-ebcf6ea572de","acronym":"KEYNOTE-E86","url":"https://clinicaltrials.gov/study/NCT04907851","created_at":"2021-06-01T18:53:39.917Z","updated_at":"2025-02-25T16:16:17.834Z","phase":"Phase 2","brief_title":"A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)","source_id_and_acronym":"NCT04907851 - KEYNOTE-E86","lead_sponsor":"Redx Pharma Plc","biomarkers":" RNF43","pipe":" | ","alterations":" RNF43 mutation","tags":["RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Prolia (denosumab) • zamaporvint (RXC004)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 12/10/2021","start_date":" 12/10/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2024-03-08"},{"id":"d1c8d534-b991-4bdd-aee5-250c8074853d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03833700","created_at":"2023-07-12T22:09:04.322Z","updated_at":"2024-07-02T16:35:16.167Z","phase":"Phase 1","brief_title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","source_id_and_acronym":"NCT03833700","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" RNF43 • APC • AXIN1 • ZNRF3","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation","tags":["RNF43 • APC • AXIN1 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-06"},{"id":"98f9903f-5399-470c-a4e4-810aaee0f5a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681248","created_at":"2022-08-29T14:58:12.640Z","updated_at":"2024-07-02T16:35:35.195Z","phase":"","brief_title":"Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT04681248","lead_sponsor":"Leap Therapeutics, Inc.","biomarkers":" RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":"","alterations":" ","tags":["RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirexatamab (DKN-01)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-09-29"},{"id":"2fd38c52-b64b-4e26-aac4-6e079d9c3e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991947","created_at":"2023-08-15T19:10:06.072Z","updated_at":"2024-07-02T16:35:39.996Z","phase":"","brief_title":"Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer","source_id_and_acronym":"NCT05991947","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-15"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"8e871962-d882-425c-bf52-00aaa004787b","acronym":"Keynote 596","url":"https://clinicaltrials.gov/study/NCT02675946","created_at":"2022-01-26T19:54:54.091Z","updated_at":"2025-02-25T16:04:17.687Z","phase":"Phase 1b","brief_title":"CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)","source_id_and_acronym":"NCT02675946 - Keynote 596","lead_sponsor":"Curegenix Inc.","biomarkers":" BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-01-26"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"8e96cc7a-6dec-4aa5-96fd-2012bb5fe9bb","acronym":"LUDOC","url":"https://clinicaltrials.gov/study/NCT02062697","created_at":"2021-01-18T09:30:05.355Z","updated_at":"2024-07-02T16:36:49.646Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","source_id_and_acronym":"NCT02062697 - LUDOC","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-25"},{"id":"0f58a0ca-0ebd-407c-a07e-347f60642792","acronym":"","url":"https://clinicaltrials.gov/study/NCT02278133","created_at":"2021-01-18T10:43:25.747Z","updated_at":"2024-07-02T16:37:17.241Z","phase":"Phase 1/2","brief_title":"Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations","source_id_and_acronym":"NCT02278133","lead_sponsor":"Array BioPharma","biomarkers":" KRAS • RNF43","pipe":" | ","alterations":" KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation","tags":["KRAS • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 06/23/2017","study_completion_date":" 06/23/2017","last_update_posted":"2017-10-09"}]